Funding for this research was provided by:
National Eye Institute (R01EY027749, R24EY028764, R24EY028764-01A1S1, R43EY031238, R43EY031643, R41EY027665)
American Diabetes Association (1-18-IBS-172)
Article History
Received: 31 March 2021
Revised: 15 June 2021
Accepted: 25 June 2021
First Online: 7 July 2021
Declarations
:
: HT and WL are shareholders of Everglades Biopharma, LLC and LigandomicsRx, LLC. WL is the inventor of pending patents related to ligandomics and anti-Scg3 therapy.
: Not applicable.
: Not applicable.
: Not applicable.